---
reference_id: "PMID:37867184"
title: "Persistent headaches one year after bacterial meningitis: prevalence, determinants and impact on quality of life."
authors:
- Van RN
- Tubiana S
- De Broucker T
- Cédric J
- Roy C
- Meyohas MC
- Prazuck T
- Chirouze C
- Hoen B
- Duval X
- Revest M
- COMBAT study group
journal: Eur J Clin Microbiol Infect Dis
year: '2023'
doi: 10.1007/s10096-023-04673-y
content_type: abstract_only
---

# Persistent headaches one year after bacterial meningitis: prevalence, determinants and impact on quality of life.
**Authors:** Van RN, Tubiana S, De Broucker T, Cédric J, Roy C, Meyohas MC, Prazuck T, Chirouze C, Hoen B, Duval X, Revest M, COMBAT study group
**Journal:** Eur J Clin Microbiol Infect Dis (2023)
**DOI:** [10.1007/s10096-023-04673-y](https://doi.org/10.1007/s10096-023-04673-y)

## Content

1. Eur J Clin Microbiol Infect Dis. 2023 Dec;42(12):1459-1467. doi: 
10.1007/s10096-023-04673-y. Epub 2023 Oct 23.

Persistent headaches one year after bacterial meningitis: prevalence, 
determinants and impact on quality of life.

Van RN(1), Tubiana S(2), De Broucker T(3), Cédric J(4), Roy C(5), Meyohas MC(6), 
Prazuck T(7), Chirouze C(8), Hoen B(9), Duval X(2)(10), Revest M(11)(12)(13); 
COMBAT study group.

Collaborators: Mourvillier B, Ploy MC, Caron F, Bollaert PE, Gaillot O, Taha MK, 
Poyart C, Bonacorsi S, Vandenesch F, Cambau E, Lecuit M, Gravet A, Frachet B, 
Bruhl DL, Raffi F, Preau M, Anguel N, Argaud L, Arista S, Armand-Lefevre L, 
Balavoine S, Baraduc R, Barnaud G, Beraud G, Bernard L, Bernars G, Bertei D, 
Bessede E, Pomares TB, Biron C, Bland S, Boileau J, Boubeau P, Bourdon S, 
Bousquet A, Boyer S, Bozorg-Grayeli A, Bret L, Bretonniere C, Bricaire F, Brocas 
E, Brun M, Buret J, Burucoa C, Cabalion J, Cabon M, Camuset G, Canevet C, Caron 
F, Carricajo A, Castan B, Caumes E, Cazanave C, Chabrol A, Challan-Belval T, 
Chanteperdrix-Marillier V, Chaplain C, Charlier-Woerther C, Chaussade H, 
Chirouze C, Clair B, Colot J, Conil JM, Cordel H, Cormier P, Cousson J, Cronier 
P, Cua E, Dao-Dubremetz A, Dargere S, Degand N, Dekeyser S, Delaune D, Denes E, 
Dequin PF, Descamps D, Descloux E, Desmaretz JL, Diehl JL, Dimet J, Dinh A, 
Escaut L, Fabe C, Faibis F, Flateau C, Fonsale N, Forestier E, Fortineau N, 
Gagneux-Brunon A, Garandeau C, Garcia M, Garot D, Gaudry S, Goehringer F, 
Gregoire-Faucher V, Grosset M, Gubavu C, Gueit I, Guelon D, Guimard T, Guinard 
J, Hadou T, Helene JP, Henard S, Henry B, Hochart AC, Hoen B, Illes G, Jaffuel 
S, Jarrin I, Jaureguy F, Joseph C, Juvin ME, Kayal S, Kerneis S, Lacassin, 
Lamaury I, Lanotte P, Laurens E, Laurichesse H, Le Brun C, Le Moing V, Le 
Turnier P, Lecuyer H, Ledru S, Legrix C, Lemaignen A, Lemble C, Lemee L, Lesens 
O, Levast M, Lhommet C, Males S, Malpote E, Martin-Blondel G, Marx M, Masson R, 
Matray O, Mbadi A, Mechai F, Mellon G, Merens A, Meyohas MC, Michon A, Yoganaden 
JM, Morquin D, Mouly S, Mrozek N, Nguyen S, Nguyen Y, Ogielska M, Oziol E, Page 
B, Patrat-Delon S, Patry I, Pechinot A, Picot S, Pierrejean D, Piroth L, 
Plassart C, Plessis P, Portel L, Poubeau P, Poupard M, Prazuck T, Quaesaet L, 
Ramanantsoa A, Rapp C, Raskine L, Raymond J, Revest M, Riche A, Robaday-Voisin 
S, Robin F, Romaszko JP, Rousseau F, Roux AL, Royer C, Saada M, Salmon D, 
Saroufim C, Schmit JL, Sebire M, Segonds C, Sivadon-Tardy V, Soismier N, Son O, 
Sunder S, Suy F, Tande D, Tankovic J, Valin N, Van Grunderbeeck N, Varon E, 
Verdon R, Vergnaud M, Vernet-Garnier V, Vidal M, Vitrat V, Vittecoq D, Vuotto F, 
Gorenne I, Laouenan C, Marcault E, Mentre F, Pasquet B, Roy C, Tubiana S.

Author information:
(1)Infectious Diseases and Intensive Care Unit, UMR_1230, BRM (Bacterial RNA and 
Medicine), Inserm, CHU Rennes, Université Rennes 1, CIC-Inserm 1414, Rennes, 
France.
(2)IAME, Inserm UMR 1137, University Paris Diderot, Sorbonne Paris Cité, France.
(3)Neurology Unit, CH Delafontaine, Saint-Denis, France.
(4)Infectious Diseases Unit, CHU Amiens, France.
(5)Epidemiology, Biostatistics and Clinical Research Unit, Bichat Claude Bernard 
Hospital, APHP, Paris, France.
(6)Infectious Diseases Unit, Saint-Antoine Hospital, APHP, Paris, France.
(7)Infectious Diseases Unit, CHU Orléans, France.
(8)Infectious Diseases Unit, CHU Besançon, France.
(9)Infectious Diseases Unit, CHU Nancy, France.
(10)Centre d'investigation Clinique, Hôpital Bichat, APHP, Inserm CIC 1425, 
Paris, France.
(11)Infectious Diseases and Intensive Care Unit, UMR_1230, BRM (Bacterial RNA 
and Medicine), Inserm, CHU Rennes, Université Rennes 1, CIC-Inserm 1414, Rennes, 
France. matthieu.revest@gmail.com.
(12)UMR-1230 BRM (Bacterial RNA and Medicine), Inserm, Université Rennes, 
Rennes, France. matthieu.revest@gmail.com.
(13)Centre d'investigation Clinique, CHU Rennes, Inserm CIC 1414, Rennes, 
France. matthieu.revest@gmail.com.

BACKGROUND: Little is known on headaches long-term persistence after bacterial 
meningitis and on their impact on patients' quality of life.
METHODS: In an ancillary study of the French national prospective cohort of 
community-acquired bacterial meningitis in adults (COMBAT) conducted between 
February 2013 and July 2015, we collected self-reported headaches before, at 
onset, and 12 months (M12) after meningitis. Determinants of persistent headache 
(PH) at M12, their association with M12 quality of life (SF 12), depression 
(Center for Epidemiologic Studies Depression Scale) and neuro-functional 
disability were analysed.
RESULTS: Among the 277 alive patients at M12 87/274 (31.8%), 213/271 (78.6%) and 
86/277 (31.0%) reported headaches before, at the onset, and at M12, 
respectively. In multivariate analysis, female sex (OR: 2.75 [1.54-4.90]; 
p < 0.001), pre-existing headaches before meningitis (OR: 2.38 [1.32-4.30]; 
p < 0.01), higher neutrophilic polynuclei percentage in the CSF of the initial 
lumbar puncture (OR: 1.02 [1.00-1.04]; p < 0.05), and brain abscess during the 
initial hospitalisation (OR: 8.32 [1.97-35.16]; p < 0.01) were associated with 
M12 persistent headaches. Neither the responsible microorganism, nor the 
corticoids use were associated with M12 persistent headaches. M12 
neuro-functional disability (altered Glasgow Outcome Scale; p < 0.01), M12 
physical handicap (altered modified Rankin score; p < 0.001), M12 depressive 
symptoms (p < 0.0001), and M12 altered physical (p < 0.05) and mental 
(p < 0.0001) qualities of life were associated with M12 headaches.
CONCLUSION: Persistent headaches are frequent one year after meningitis and are 
associated with quality of life alteration.
CLINICAL TRIAL: NCT01730690.

© 2023. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, 
part of Springer Nature.

DOI: 10.1007/s10096-023-04673-y
PMID: 37867184 [Indexed for MEDLINE]